Status:
COMPLETED
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Immune Thrombocytopenic Purpura
Autoimmune Hemolytic Anemia
Eligibility:
All Genders
Up to 18 years
Brief Summary
In France, a national prospective cohort for monitoring children and adolescents with autoimmune cytopenia OBS'CEREVANCE is in place since 2004. It is coordinated in Bordeaux by the Center's team. Ref...
Detailed Description
Chronic immunological thrombocytopenic purpura and anemia hemolytic autoimmune are rare autoimmune hematologic diseases, primary or secondary, affecting the child often very young, sometimes associate...
Eligibility Criteria
Inclusion
- Patient initiating a first second-line immunomodulatory treatment (azathioprine, ciclosporine, eltrombopag, hydroxychloroquine, mycophénolate mofétil, rituximab, romiplostim), registered in the OBS'CEREVANCE database, presenting a Chronic Immune-Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia or simultaneous EVANS syndrome.
Exclusion
- Patient under immunosuppressant for another immunological pathology at the initiation of the first second line treatment,
- Patient treated with 2 second-line treatments on the same day,
- Oral refusal of participation of the patient or his legal representatives, after reading the information note specific for the study.
Key Trial Info
Start Date :
January 18 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 4 2016
Estimated Enrollment :
454 Patients enrolled
Trial Details
Trial ID
NCT04057703
Start Date
January 18 2016
End Date
December 4 2016
Last Update
August 15 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.